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Catechol-O-methyltransferease (COMT) metabolizes prefrontal cortex dopamine (DA), a neurotransmitter involved in executive
behavior; the Val158Met genotype has been linked to executive dysfunction, which might increase sexual risk behaviors favoring
HIV transmission. Main and interaction effects of COMT genotype and executive functioning on sexual risk behavior were
examined. 192 sexually active nonmonogamous men completed a sexual behavior questionnaire, executive functioning tests, and
were genotyped using blood-derived DNA. Main effects for executive dysfunction but not COMT on number of sexual partners
were observed. A COMT x executive dysfunction interaction was found for number of sexual partners and insertive anal sex,
significant for carriers of the Met/Met and to a lesser extent Val/Met genotypes but not Val/Val carriers. In the context of HIV
and methamphetamine dependence, dopaminergic overactivity in prefrontal cortex conferred by the Met/Met genotype appears
to result in a liability for executive dysfunction and potentially associated risky sexual behavior.
1. Introduction
HIV infection is a global pandemic and the population
is growing due to successful treatment with highly active
antiretroviral therapy (HAART) [1]. Although rates of HIV
have been reduced in the United States among most groups
as a result of successful public health efforts (e.g., condom
accessibility, education programs, media campaigns), sexual
risk behavior and subsequent acquisition and/or spread of
HIV and other sexually transmitted infections are still of
concern among men who have sex with men as well as
drug using populations [1]. Thus, it is evident that, despite
research and efforts to understand and curb sexual risk
behavior within these vulnerable populations, additional
work employing novel approaches are needed.
Sexual risk behaviors can be viewed as a composite of
numerous behaviors that collectively make-up a complex
behavioral phenotype. As with most complex phenotypes,
sexual risk behavior is heterogeneous and several factors
contribute to the variance that can be observed from one
individual to another. To date, a majority of work examining
risk factors for sexual risk behavior phenotypes have primar-
ily focused on psychosocial factors (reviewed in [2]) and/or
other complex/heterogeneous behavioral phenotypes such
as substance use behaviors [3, 4] as indicators for current
or future sexual risk behavior. Ultimately these indicators,
upon sufficient replication, become candidates for public
health interventions that aim to prevent and reduce sexual
risk behaviors. However, the trouble with many of these
candidates is that they are too proximal to sexual risk behav-
iors and often cooccur, making it difficult to disentangle
temporal precedence and ultimately limit prevention efforts.
One relatively novel approach is to examine intermediate
phenotypes or endophenotypes [5] such as neurocognitive
2 Interdisciplinary Perspectives on Infectious Diseases
factors as well as biological (i.e., genetic) factors. These
factors are more distal to the onset of sexual risk behavior
and thus are potentially more advantageous candidates for
identifying vulnerable individuals and informing prevention
efforts for sexual risk behavior.
Studies in literature examining neurocognitive and bio-
logical factors as indicators for sexual risk behaviors are
limited. In fact, only two studies to date have examined
neurocognitive factors [6, 7] and none to our knowledge
have examined biological factors as potential indicators.
Although this paucity of research is surprising given
previous work linking both neurocognitive [8–10] and
genetic [11–13] indicators to other health related behaviors,
research has established the dopminergic system as a com-
mon link between neurocognitive functioning and sexual
behavior.
The dopminergic system has been shown to be involved
in sexual arousal, motivation and the subsequent rewarding
effect of sexual behavior (for detailed review see [14]).
Furthermore, DA in the human brain, specifically in the
prefrontal cortex (PFC), has been shown to be necessary
for proper cognitive functioning to occur and high or low
levels of DA in this brain region are known to contribute to
individual cognitive differences in humans [15, 16]. The PFC
is of particular importance when examining risk behavior in
that executive functions such as decision-making, planning,
self-monitoring as well as behavior initiation, organization,
and inhibition are largely dependent on PFC integrity
[17]. Impairment in executive functioning may result in
difficulties in assessing relationships between a person’s
current behavior and future outcomes; thereby resulting
in choices and/or responses on the premise of immediate
rewards (e.g., pleasure, social acceptance) versus long-
term consequences (e.g., viral infections) and an ultimate
potential increase in the likelihood for participation in sexual
risk behaviors (e.g., unprotected sex, multiple partners)
[7, 18]. Thus, mechanisms responsible for maintaining a
dopamine balance within the brain and in particular the PFC
would appear to be good biological candidates for further
exploration of an association between executive dysfunction
and sexual risk behavior.
One such candidate is catechol-O-methyltransferease
(COMT) which is a mammalian enzyme involved in the
metabolic degradation of released dopamine, particularly
in the PFC [19]. Of particular interest to this study is a
common polymorphism involving a Val to Met substitution
at codon 158. The Val allele of the COMT Val158Met
polymorphism is 40% more enzymatically active than the
Met allele [20]. Thus, carriers of the Met allele metabolize
dopamine at a less efficient rate, resulting in higher levels
of dopamine in the synapse and ultimately an escalation
in dopamine receptor activation. This differentiation of
dopamine receptor activity dependent on COMT genotype
has led to several investigations into the relationship between
COMT and executive dysfunction in which the Val allele
has been putatively linked to poor performance on executive
functioning tasks [21]. However, to our knowledge no work
has examined the relationship between COMT and sexual
risk behavior; albeit studies of similar behaviors such as
novelty seeking [22–24], reward dependence [22], as well
as affective arousal and regulation [25] have demonstrated
significant relationships.
Given the aforementioned paucity of research in the
current literature addressing the contribution of genetic
and neurocognitive factors on sexual risk behavior, the
primary aim of this study was to examine the main effects
of executive functioning as well as the main effects of the
COMT Val158Met polymorphism on sexual risk behavior
among a ethnically diverse population of men with and
without METH dependence and/or HIV infection. Within
this aim, we hypothesized that the highly active COMT
Val/Val genotype and its putatively associated deficits in exec-
utive functioning would be independently associated with
sexual risk behaviors. In addition, as a result of previously
mentioned research that has demonstrated an association
between COMT genotype and executive functioning we also
explored the potential interaction effects of COMT and
executive dysfunction on sexual risk behavior.
2. Methods
2.1. Participants. Participants were volunteers evaluated at
the HIV Neurobehavioral Research Center (HNRC) at
the University of California in San Diego as part of a
cohort study focused on central nervous system effects
of HIV and methamphetamine. The current study com-
prised 192 sexually active non-monogamous men with
and without methamphetamine dependence (METH+/−)
and/or HIV infection (HIV+/−). Men were classified as non-
monogamous if they stated they had “no current partner”
at time of assessment. Monogamous men were excluded
because unsafe sexual behavior within a monogamous rela-
tionship is less risky than in non-monogamous relationships
[26].
All participants underwent a comprehensive characteri-
zation procedure that included collection of demographic,
neuromedical, psychiatric as well as neuropsychiatric infor-
mation. HIV serological status was determined by enzyme
linked immunosorbent assays (ELISA) plus a confirma-
tory test. Lifetime METH dependence was determined by
the Structured Clinical Interview for the Diagnostic and
Statistical Manual of Mental Disorders Version IV (SCID-
IV). However, participants were not actively using other
substances, with the exception of cannabis and alcohol.
Potential participants were excluded if they met lifetime
dependence criteria for other drugs, unless the dependence
was judged to be remote (more than 5 years ago) and episodic
in nature by a doctoral level clinician. Alcohol dependence
within the last year was also an exclusion criterion. All
participants were seronegative for hepatitis C infection.
Additional information for each participant was collected
as it relates to current depressed mood as well as lifetime
diagnosis of Major Depression Disorder (MDD) and/or
Bipolar Disorder I or II. Current depressed mood was
assessed utilizing the Beck Depression Inventory-I (BDI-I)
[27] and MDD and Bipolar Disorder were ascertained using
the SCID-IV. Information was also collected to determine
lifetime dependence on sedatives, cannabis, opioids, cocaine,
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hallucinogens, and alcohol, using the SCID-IV. For METH+
participants, additional information was collected regarding
age at first use, years of use, and days since last use of METH;
whereas for HIV+ participants, HIV RNA plasma copies
was ascertained as part of a larger neuromedical evaluation.
All participants gave written consent prior to enrollment
and all procedures were approved by the Human Research
Protection Program of the University of California, San
Diego and San Diego State University.
2.2. Executive Functioning. Executive functioning was deter-
mined as part of a larger comprehensive battery of tests
covering seven ability domains (Learning, Memory, Atten-
tion/Working Memory, Verbal Fluency, Processing Speed,
Abstraction/Problem Solving, and Motor Speed). The exec-
utive functioning domain deficit score, of particular focus
in this study, was made up of (1) perseverative responses
on the Wisconsin Card Sorting Test [28]; (2) errors on the
Halstead Category Test [29], which measures abstraction
and cognitive flexibility; and (3) time to complete the Trail
Making Test part B (Trails B) [30], reflecting ability to
switch and maintain attention between ongoing sequences.
Raw scores for each of these component tests were con-
verted to demographically-adjusted T-scores (M = 50,
SD= 10), including adjustments for age, education, gender,
and ethnicity as available for each test. The demographically-
adjusted T-scores for each test were then converted into
deficit scores, which reflect degree of impairment by setting
performances within the normal range at zero with a range
from 0 (T-score > 39; no impairment) to 5 (T-score <
20; severe impairment). Finally, the individual deficit scores
were averaged to derive the domain deficit score, which
reflects the severity of executive functioning deficit. Previous
work has demonstrated that deficit scores achieve good
diagnostic agreement with classifications made by blind
clinical ratings [31, 32]. All neurocognitive testing and
scoring was performed by trained psychometrists blinded to
participants’ genotypes.
2.3. Sexual Risk Behavior. Sexual risk behavior was assessed
through an HNRC-developed self-report measure covering
the preceding year. Information was gathered with regard
to age at first intercourse as well as number of different
sex partners. Age at time of first intercourse was coded in
years for both male and female partners. However, when two
different ages were given for first intercourse, the younger of
the two ages was used. In addition, participants were asked
to indicate the percentage of time that they used a condom as
well as engaged in oral, vaginal, anal (receptive & insertive)
and/or intoxicated sex. Responses were recorded on a 6-
item, Likert-type scale with a value of 0= 0%, 1= 1%–5%,
2= 6%–25%, 3= 26%–50%, 4= 51%–75% and 5= 76%–
100%.
2.4. DNA Extraction and Genotyping. DNA was extracted
from peripheral blood mononuclear cells stored (three to five
years) at −70◦C using the QIAamp DNA Mini kit (Qiagen,
Valencia, CA; Catalog #51185). The COMT Val158Met
polymorphism (rs4680) was assayed along with eight other
SNPs as part of a concurrent genetic association project
at the HNRC. A multiplex PCR technique designed using
Sequenom SpectroDESIGNER software (version 3.0.0.3) was
employed by inputting a sequence containing 100 bp of
flanking sequence on either side of the COMT Val158Met
polymorphism. The SNP was then grouped into multiplexes
so that the extended product would not overlap in mass
with any other oligonucleotide present in the reaction mix,
and where no primer-primer, primer-product, or non-
specific interactions would occur. The PCR was carried
out in 384-well reaction plates in a volume of 5 μl using
10 ng genomic or whole-genome amplified (WGA) DNA. All
subsequent steps, up until the reaction, were spotted onto
the SpectroCHIP and carried out in the same reaction plate.
After PCR, any unincorporated dNTPs from the PCR were
removed from the reaction by digestion with Shrimp alkaline
phosphatase. dNTPs were removed so that they could not
play any role in the extension of the oligonucleotide at the
SNP site. The extension reaction was then carried out in the
presence of the extension oligonucleotide and a termination
mix containing mass-modified dideoxynucleotides which
extended the oligonucleotide over the SNP site with one
base. Before spotting onto the SpectroCHIP, the reaction
was cleaned by incubation with a cation-exchange resin
which removed any salts present. The extension product
was then spotted onto a 384-well spectroCHIP before
being flown in the MALDI-TOF mass spectrometer. Data
were collected, in real time, using SpectroTYPER Ana-
lyzer 3.3.0.15, SpectraAQUIRE 3.3.1.1 and SpectroCALLER
3.3.0.14 (Sequenom) algorithms. All genotyping was per-
formed by an accredited commercial laboratory (Harvard
Medical School-Partners Healthcare Center for Genetics and
Genomics, Cambridge, MA CLIA no. 22D1005307).
2.5. Statistical Analysis. All statistical tests and procedures
were conducted using SPSS 10.0 (SPSS, 2000). Univariate
comparisons across the three COMT genotypes (i.e., Val/Val,
Val/Met, Met/Met) were performed using one-way analysis
of variance (ANOVA) for continuous and chi-squared tests
for categorical variables. In cases, where data violated
normality assumptions medians were calculated and non-
parametric tests (i.e., Kruskal-Wallis) performed. To examine
the main and explore the interaction effects of executive
functioning and COMT on sexual risk behaviors, hierarchi-
cal multiple linear regressions in accord with Barron and
Kenny’s approach [33] were conducted for each of the seven
sexual risk behaviors (see Section 2.3) under study. Prior
to running each analysis, the executive functioning variable
was centered and the COMT genotype contrast coded to
reduce problems resulting from multicollinearity (Kraemer
and Blasey, 2004). In addition, interaction terms were created
by multiplying COMT genotype by the centered executive
functioning variable. Next, multiple linear regressions were
used to examine potential confounders based on univariate
genotype comparisons described above. These confounders
included: ethnicity, METH status, HIV status and age at first
intercourse. We also included BDI scores based on inclusion
of this measure in recent work testing a similar hypothesis
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[7]. Results showed that METH status, HIV status, and age at
first intercourse accounted for a significant unique variance
for all sexual behaviors under investigation (R2 range:
0.06–0.39, Ps < .02). Thus to control for these potential
confounding effects, the residuals derived from each of
the sexual behavior models were used as the dependent
variables for all subsequent regression models. The centered
executive functioning variable and COMT genotype as well
as the new interaction term were then entered as indepen-
dent variables into seven individual hierarchical multiple
regression models using the residuals described above as
the dependent variable. For models in which a significant
interaction was observed, a final round of regressions were
conducted stratified by COMT genotype to determine the
nature of the interaction between executive functioning and
COMT on the particular sexual risk behavior. Due to the
exploratory nature of the interaction analysiswe selected a
relaxed alpha threshold alpha < .10 to reduce Type II errors,
albeit the traditional alpha threshold of .05 was used for all
other analyses.
3. Results
3.1. Participant Characteristics. Characteristics of the full
sample by each of the three COMT genotypes are summa-
rized in Table 1. All three genotype groups were comparable
in age, education, sexual behavior, executive functioning,
as well as psychiatric and substance dependence histories.
However, Val/Val carriers were significantly more likely to
identify as African-American (χ2 = 17.67, P= .001), report
an earlier age of first intercourse (F(2,189) = 3.51, P= .032),
and be seropositive for HIV (χ2 = 6.57, P = .038). Whereas,
Met-carriers (i.e., Met/Met or Val/Met) were significantly
more likely to identify as Caucasian (χ2 = 14.32, P = .001).
Additionally, among METH+ participants Val/Val carriers
reported significantly greater total years of METH use
(F(2,87) = 3.12, P = .050) compared to their Met-carrying
counterparts.
3.2. Main Effects of Executive Functioning and COMT.
Table 2 provides standardized multiple linear regression
coefficient estimates for main and interaction effects of
executive functioning and COMT genotype for each of
the seven sexual risk behaviors adjusting for METH status,
HIV status, and age at first intercourse. A significant
main effect for the executive functioning domain deficit
score was observed for number of partners (β = 0.21,
P = .005). Additionally, results from the individual executive
functioning tests showed a significant main effect for T-
scores on the Wisconsin Card Sort and Halstead Category
tests in adjusted models of oral sex (β = 0.20, P = .009)
and condom use (β = −0.16, P = .030), respectively. Main
effects were not observed for COMT genotype in any of the
regression models.
3.3. Interaction Effects of Executive Functioning and COMT.
Applying an exploratory cut-off of P < .10, significant
interactions between the executive functioning domain
deficit score and COMT were observed for number of sexual
partners (β = 0.50, P = .038), insertive anal sex (β = 0.50,
P = .046), and receptive anal sex (β = 0.50, P = .081)
(Table 2). Subsequent stratified analysis by COMT genotype,
revealed that among carriers of the Met/Met (β = 0.52,
P = .001) and to a lesser extent Val/Met (β = 0.20, P = .048)
genotype, increases in the executive functioning domain
deficit score was significantly associated with increases in the
number of sexual partners in the past 12 months. Stratified
analysis for insertive and receptive anal sex revealed similar
results. Among Met/Met and Val/Met carriers, an increase
in executive deficit scores were associated with an increased
frequency of insertive (Met/Met: β = 0.18; Val/Met: β =
0.11) and receptive (Met/Met: β = 0.13; Val/Met: β =
0.11) anal sex in the past 12 months, albeit not statistically
significant.
Results of regression analyses to examine interactions
between each of the three individual executive functioning
tests and COMT genotype are also shown in Table 2. For
the Wisconsin Card Sort Test no interactions were observed.
However, for Trails B, significant interactions with COMT
were observed for insertive (β = −0.99, P = .015) and
receptive (β = −0.75, P = .066) anal sex, as well as oral
sex (β = −0.68, P = .096). Stratified regression analysis
showed that among carriers of the Met/Met genotype, poor
performance on Trails B (i.e., low T-scores) was significantly
associated with an increased frequency of insertive (β =
−0.38, P = .028) but not receptive (β = −0.22, P =
.225) anal sex. Interestingly, among carriers of the Val/Val
genotype, T-scores on Trails B had a significant positive
association with oral sex (β = 0.35, P = .013). Finally, for
the Halstead Category Test, a single interaction with COMT
was observed for condom use (β = −1.13, P = .006). Among
carriers of the Met/Met (β = −0.49, P = .004) and to
a lesser extent Val/Met (β = −0.19, P = .064) genotype,
Halstead Category Test T-scores were negatively associated
with condom use.
4. Discussion
To our knowledge this study is the first to examine main
effects as well as explore the interaction effects of COMT
genotype and executive functioning on sexual risk behavior.
Our main findings suggest significant executive dysfunction
main effects for number of sexual partners as well as
frequency of oral sex and condom use. In addition, results
of our exploratory interaction analyses provide evidence
that COMT genotype and executive dysfunction interact in
models of number of sexual partners, condom use, insertive
and receptive anal sex, as well as oral sex. Stratified analyses
further suggest that the strength of these associations is
dependent on the number of Met alleles the individual was
carrying, with the exception of oral sex in which Val/Val was
the informative genotype.
Our significant executive dysfunction main effects for
sexual risk behaviors are discordant with the only other
study, to our knowledge, that has examined the association
between executive dysfunction and sexual risk behavior [7].
In that study, no association was found between executive
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Table 1: Characteristics of full sample by COMT genotype.
COMT genotype
Full sample Val/Val Val/Met Met/Met
(n = 192) (n = 54) (n = 103) (n = 35)
Age (years) M (sd) 37 (9) 35 (9) 38 (9) 39 (11)
Education (years) M (sd) 13 (2) 13 (2) 13 (2) 14 (2)
WRAT4 M (sd) 100 (12) 99 (11) 100 (12) 104 (11)
Ethnicity (row %)
Caucasian 71 52 78 83 v/v < v/m, m/m∗∗
African-American 15 32 7 11 v/v > v/m, m/m∗∗
Hispanic 14 17 16 6
Executive Functioning Battery
Wisconsin card sort test T (sd) 45 (14) 47 (16) 44 (13) 46 (13)
Trials part B T (sd) 49 (11) 51 (12) 47 (10) 52 (11)
Halstead category Test T (sd) 46 (10) 47 (10) 44 (10) 47 (9)
Domain deficit score M (sd) .55 (.69) .56 (.68) .62 (.74) .35 (.47)
Executive impairment (%) 45 46 50 31
Sexual Characteristics/Behavior
Age at first intercourse M (sd) 15 (4) 14 (4) 16 (4) 17 (4) v/v < m/m∗
Sexual preference (% heterosexual) 33 35 31 38
Number partners in past 12 mo Median (IQR) 3 (1,10) 4 (1, 11) 3 (1, 10) 2 (1, 5)
Condom use (>0% in past 12 mo) 72 74 71 70
Insertive anal (>0% in past 12 mo) 62 60 67 52
Receptive anal (>0% in past 12 mo) 58 60 62 46
Oral sex (>0% in past 12 mo) 93 94 93 94
Intoxicated sex (>0% in past 12 mo) 64 63 66 61
Vaginal sex (>0% in past 12 mo) 37 35 35 44
DSM-IV Psychiatric Disorder (% lifetime)
Major depression 36 36 35 40
Bipolar I or II 4 8 3 3
Beck depression inventory M (sd) 12 (9) 11 (8) 13 (10) 10 (9)
DSM-IV Substance Dependence (% lifetime)
Sedative 0 0 0 0
Cannabis 9 9 11 6
Opioid 0 0 0 0
Cocaine 7 7 5 14
Hallucinogen 0 0 0 0
Alcohol 17 15 20 14
Methamphetamine Parameters
Methamphetamine dependent (%) 47 37 52 49
Age at first METH use, yrs M (sd) 24 (9) 23 (9) 25 (8) 27 (10)
Total METH use, yrs M (sd) 11 (6) 13 (7) 11 (6) 8 (4) v/v > m/m∗
Last use of METH, days Median (IQR) 91 (36, 274) 122 (45, 731) 91 (32, 236) 91 (30, 244)
HIV Parameters
HIV seropositive (%) 56 70 51 49 v/v > v/m, m/m∗
HIV RNA, plasma (log copies/mL) M (sd) 2.1 (1.9) 2.4 (1.7) 2.0 (2.0) 1.7 (1.9)
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Table 2: Multivariate linear regression coefficients for main, interaction, and stratified effects of executive functioning and COMT in seven
sexual risk behavior models.
Standardized Beta(a)
Main Effect Interaction Straitfied(b)
EF measure EF COMT EF × COMT Val/Val Val/Met Met/Met
Sexual Risk Behavior Model (n = 192) (n = 192) (n= 192) (n= 54) (n= 103) (n= 35)
Domain Deficit Score
(1) Partners (# past 12 mo) 0.21∗∗ 0.10 0.50∗∗ 0.03 0.20∗∗ 0.52∗∗∗
(2) Condom use (% past 12 mo) 0.03 0.13 0.24 — — —
(3) Insertive anal (% past 12 mo) 0.06 0.07 0.50∗∗ −0.18 0.11 0.18
(4) Receptive anal (% past 12 mo) 0.05 0.05 0.44∗ −0.17 0.11 0.13
(5) Oral sex (% past 12 mo) −0.10 0.07 0.40 — — —
(6) Intoxicated sex (% past 12 mo) 0.07 −0.06 0.08 — — —
(7) Vaginal sex (% past 12 mo) −0.03 −0.04 −0.28 — — —
Wisconsin Card Sort Test (T-score)
(1) Partners (# past 12 mo) −0.09 0.08 −0.18 — — —
(2) Condom use (% past 12 mo) −0.10 0.12 −0.25 — — —
(3) Insertive anal (% past 12 mo) 0.01 0.07 −0.31 — — —
(4) Receptive anal (% past 12 mo) −0.02 0.04 −0.38 — — —
(5) Oral sex (% past 12 mo) 0.20∗∗ 0.09 0.13 — — —
(6) Intoxicated sex (% past 12 mo) −0.04 −0.07 0.32 — — —
(7) Vaginal sex (% past 12 mo) 0.04 −0.04 −0.04 — — —
Trails B (T-score)
(1) Partners (# past 12 mo) −0.01 0.08 −0.54 — — —
(2) Condom use (% past 12 mo) −0.07 0.11 0.03 — — —
(3) Insertive anal (% past 12 mo) −0.06 0.06 −0.99∗∗ 0.18 −0.03 –0.38∗∗
(4) Receptive anal (% past 12 mo) −0.04 0.03 −0.75∗ 0.17 −0.06 −0.22
(5) Oral sex (% past 12 mo) 0.10 0.06 −0.68∗ 0.35∗∗ 0.01 0.01
(6) Intoxicated sex (% past 12 mo) −0.11 −0.07 0.13 — — —
(7) Vaginal sex (% past 12 mo) 0.07 −0.04 0.37 — — —
Halstead Category Test (T-score)
(1) Partners (# past 12 mo) −0.11 0.08 −0.16 — — —
(2) Condom use (% past 12 mo) −0.16∗∗ 0.11 −1.13∗∗ 0.08 –0.19∗ –0.49∗∗∗
(3) Insertive anal (% past 12 mo) 0.01 0.05 −0.22 — — —
(4) Receptive anal (% past 12 mo) −0.01 0.03 −0.59 — — —
(5) Oral sex (% past 12 mo) 0.06 0.06 −0.50 — — —
(6) Intoxicated sex (% past 12 mo) −0.04 −0.06 −0.44 — — —
(7) Vaginal sex (% past 12 mo) −0.05 −0.04 0.25 — — —
(a)all regression models adjusted for METH status, HIV status, age at first intercourse.
(b)stratified analysis of EF effects by genotype was conducted if a significant (P < .10) interaction was observed.
EF: executive functioning; COMT: catechol-O-methyltransferease (0 = Val/Val; 1 = Val/Met; 2 =Met/Met)
∗P < .10; ∗∗P < .05, ∗∗∗P < .005.
dysfunction and sexual risk behavior among an African-
American sample of men and women poly-substance abusers
with and without HIV infection. However, three major
methodological differences may explain our discordant
findings. First, Gonzalez et al. [7] estimated sexual risk
behavior in the past 6 months compared to our window of
12 months and also utilized a composite score rather than
individual sexual risk behaviors as their dependent variable.
Second, executive dysfunction was assessed using the Iowa
Gambling Task, delayed non-matching to sample paradigm,
and Stroop task-reaction time version which, respectively,
measure decision-making, working memory, and response
inhibition. Although these tests are well justified, other
components of executive functioning such as perseveration,
cognitive sequencing, and concept formation which were
assessed in the current study, were not examined. Third
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Figure 1: A theoretical model illustrating the interaction effect
of a single genotype (i.e., COMT Val158Met polymorphism) and
endophenotype (i.e., executive functioning domain deficit) on a
behavioral phenotype (i.e., number of sexual partners). Among
carriers of the COMT Met/Met and to a lesser extent the Val/Met
genotype the association between executive functioning deficit and
number of sexual partners is significantly stronger than among
carriers of the Val/Val genotype. ∗P < .05; ∗∗P < .01.
and finally, regression models were adjusted for sensation
seeking, a factor shown in previous research to be associated
with sexual risk behavior [34–37]; however, in the current
study sensation seeking data was not available and was not
adjusted for. Thus, future work examining the association
between executive dysfunction and sexual risk behaviors are
warranted; particularly research utilizing larger samples with
diverse measures of executive functioning and models adjust-
ing for sensation seeking and other personality covariates.
Novel to the current study, we demonstrated several
genotype (i.e., COMT) by endophenotype (i.e., executive
dysfunction) interactions for sexual risk behaviors. A relaxed
significance criterion (P < .10) produced significant interac-
tions for number of sexual partners, condom use, insertive
and receptive anal sex, as well as oral sex. These interactions
collectively advocate for further investigation of genotype-
endophenotype interactions for sexual risk behavior. How-
ever, due to the exploratory nature of these interactions
our discussion will be confined to interactions observed for
number of sexual partners, frequency of insertive anal sex
and condom use, as interactions observed in these models
met the traditional significance criterion (P < .05).
We observed both a main and interaction effect for
number of sexual partners, albeit only within the model
including the composite executive functioning deficit score.
In this model we found that among carriers of the Met allele
(i.e., Met/Met or Val/Met), a positive association between
executive functioning deficit and number of sexual partners
was present. Thus, among Met allele carriers those with
greater deficit scores reported greater number of sexual
partners; whereas among Val/Val carriers this association
was not significant. Similar to results for number of sexual
partners, stratified analysis showed that among carriers of
the Met/Met but not Val/Met or Val/Val genotype an positive
association between executive dysfunction and frequency of
insertive anal sex was present, although only statistically
significant for models including the Trails B test. Thus,
individuals with lower T-scores (i.e., greater impairment)
on Trails B reported greater frequency of insertive anal sex
only if they were carriers of the Met/Met genotype. Finally,
the strongest interaction observed was between COMT
and the Halstead Category Test for frequency of condom
use. Contrary to the expected association, results suggest a
negative association among carriers of the Met/Met genotype
in which lower T-scores (i.e., greater impairment) on the
Category Test was associated with an increased frequency
of condom use. This unexpected finding may be a result
of several factors. First, the psychometric properties of the
questionnaire used to measure sexual risk behaviors in our
study have not been reported and thus measurement error
may be influencing our reported associations. Although
there is no agreed upon “gold-standard” for measuring
sexual risk behavior, recommendations from a review of 56
sexual risk behavior measures in the literature have been
developed [38] and future studies should be encouraged to
adopt these measurement strategies to improve accuracy of
sexual risk behavior characterization. Second, recall deficits
may result in sexual risk behavior reporting errors. This is
particularly a concern when measuring sexual risk behavior
retrospectively over large spans of time (i.e., 12 months)
as was done in the current study. Post-hoc analysis within
our sample showed no significant difference in recall deficit
by COMT genotype, albeit there did appear to be a trend
(F(2,189) = 2.89; P = .058) in which carriers of the Val/Val
genotype had greater deficits than that of Val/Met and
Met/Met genotypes (data not shown). Thus, it is possible
that recall deficits within the Val/Val group biased our
findings toward those in the Met/Met group and should be
interpreted with caution. Finally and most speculative, harm
reduction campaigns have long aimed to increase condom
use within both HIV-infected and METH using populations
and our finding may be an artifact of their success.
Collectively, these findings provide a preliminary model
of differential susceptibility to sexual risk behavior via
executive dysfunction, dependent on COMT genotype, par-
ticularly the Met/Met genotype (Figure 1). Although the role
of the Met/Met genotype is contrary to our hypothesis,
our findings, when placed in the context of previous
research are informative. Recent research has linked the
COMT Met/Met genotype to novelty seeking behavior in
healthy [39] and methamphetamine using [24] populations.
In addition, work by Gonzalez et al. [7] on executive
functioning and sexual risk behavior demonstrated that
sensation seeking was independently associated with sexual
risk, particularly among HIV-seropositive individuals. Thus,
it appears that individuals with the Met/Met genotype
may have a lower tolerance for monotony and may seek
and participate in higher risk behaviors such as METH
use or unprotected sex. Furthermore, work by our group
and others [40] have suggested that possession of the Met
allele enhances executive functioning in healthy controls;
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however, this neuroprotective effect is significantly reduced
among individuals exposed to methamphetamine. Thus, it
is probable that in our sample, of which approximately half
were methamphetamine dependent, the putative protective
effect of the Met/Met genotype is diminished and propensity
to sexual risk behavior enhanced.
It is apparent that the associations between COMT,
executive dysfunction, and sexual risk behavior are highly
complex and context dependent. The current study provides
preliminary evidence of these complex relationships and
advocates for larger investigations that improve upon and
consider several of the limitations that have been presented.
Future work should also attempt to address independent
and interaction effects of other putative polymorphisms
particularly those involved in dopamine synthesis (e.g.,
Tyrosine Hydroxylase), metabolism (e.g., Monoamine Oxi-
dase A), and reception (e.g., Dopamine Receptors D1-4).
In addition, future transdisciplinary work that combines
genetic and neurocognitive factors with psychosocial (e.g.,
trauma, stress) factors will provide valuable insights and
elucidate a clearer picture of sexual risk behavior. Com-
pletion of such work in combination with the current as
well as others previous work will further our understanding
of the genotypic and endophenotypic factors involved in
the phenotypic expression of sexual risk behaviors and
potentially assist with risk identification, prevention, and
treatment efforts in the future.
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